BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...Amphastar Pharmaceuticals Inc.; Actavis plc (NYSE:ACT) Enoxaparin (LMWH) Approved DVT Merck & Co. Inc. (NYSE:MRK); Endotis Pharma...
BioCentury | Oct 3, 2011
Clinical News

EP217609 regulatory update

...is in preclinical testing for the indication. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Jun 27, 2011
Clinical News

EP217609: Phase IIa started

...vs. heparin in 36 patients undergoing cardiac surgery. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Dec 6, 2010
Clinical News

EP217609: Additional Phase I data

...specific antidote avidin triggered rapid, complete and irreversible neutralization of EP217609 with no rebound effect. Endotis...
...and specific coagulation tests (see BioCentury, May 10). Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Jul 12, 2010
Clinical News

Endotis, Merck preclinical data

...factors Xa and IIa in Phase I testing. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | May 10, 2010
Clinical News

EP217609: Phase I data

...increases in both standard and specific coagulation tests. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Nov 9, 2009
Company News

Catalent Pharma, Endotis deal

...The companies will co-develop oral formulations of synthetic oligosaccharides, including Endotis' EP37151. The companies plan to...
...atrial fibrillation. The companies have been working together to use Catalent's drug delivery technology with Endotis'...
...oligosaccharides since 2008. Further terms were not disclosed. Catalent Pharma Solutions Inc. , Somerset, N.J. Endotis Pharma...
BioCentury | Oct 26, 2009
Clinical News

EP217609: Phase I started

...I trial to evaluate 1, 3 and 10 mg IV EP217609 in 40 healthy volunteers. Endotis...
...from Schering-Plough, which is being acquired by Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Endotis Pharma...
BioCentury | Jun 1, 2009
Clinical News

EP42675: Phase I data

...be presented at the International Society of Thrombosis and Hemostasis meeting in Boston in July. Endotis...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) market Plavix. Endotis Pharma...
BioCentury | Jan 24, 2008
Financial News

Endotis raises EUR 25 million

...new investors Endeavour Vision and NIF SMBC Ventures and existing investor Sofinnova Partners also participated. Endotis'...
...Xa and thrombin that is in Phase I testing to prevent arterial thrombosis. Last year, Endotis...
Items per page:
1 - 10 of 11
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...Amphastar Pharmaceuticals Inc.; Actavis plc (NYSE:ACT) Enoxaparin (LMWH) Approved DVT Merck & Co. Inc. (NYSE:MRK); Endotis Pharma...
BioCentury | Oct 3, 2011
Clinical News

EP217609 regulatory update

...is in preclinical testing for the indication. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Jun 27, 2011
Clinical News

EP217609: Phase IIa started

...vs. heparin in 36 patients undergoing cardiac surgery. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Dec 6, 2010
Clinical News

EP217609: Additional Phase I data

...specific antidote avidin triggered rapid, complete and irreversible neutralization of EP217609 with no rebound effect. Endotis...
...and specific coagulation tests (see BioCentury, May 10). Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Jul 12, 2010
Clinical News

Endotis, Merck preclinical data

...factors Xa and IIa in Phase I testing. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | May 10, 2010
Clinical News

EP217609: Phase I data

...increases in both standard and specific coagulation tests. Endotis has rights to EP217609 from Merck. Endotis Pharma...
BioCentury | Nov 9, 2009
Company News

Catalent Pharma, Endotis deal

...The companies will co-develop oral formulations of synthetic oligosaccharides, including Endotis' EP37151. The companies plan to...
...atrial fibrillation. The companies have been working together to use Catalent's drug delivery technology with Endotis'...
...oligosaccharides since 2008. Further terms were not disclosed. Catalent Pharma Solutions Inc. , Somerset, N.J. Endotis Pharma...
BioCentury | Oct 26, 2009
Clinical News

EP217609: Phase I started

...I trial to evaluate 1, 3 and 10 mg IV EP217609 in 40 healthy volunteers. Endotis...
...from Schering-Plough, which is being acquired by Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). Endotis Pharma...
BioCentury | Jun 1, 2009
Clinical News

EP42675: Phase I data

...be presented at the International Society of Thrombosis and Hemostasis meeting in Boston in July. Endotis...
...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) market Plavix. Endotis Pharma...
BioCentury | Jan 24, 2008
Financial News

Endotis raises EUR 25 million

...new investors Endeavour Vision and NIF SMBC Ventures and existing investor Sofinnova Partners also participated. Endotis'...
...Xa and thrombin that is in Phase I testing to prevent arterial thrombosis. Last year, Endotis...
Items per page:
1 - 10 of 11